Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520linagliptin

# Tradjenta (linagliptin) ## Overview Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus. It works by increasing incretin levels, which leads to increased insulin release and decreased glucagon secretion. ## Primary Indications Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ## Adult Dosing The recommended dose is 5 mg once daily. ## Pediatric Dosing Safety and efficacy have not been established in pediatric patients. ## Dose Adjustments No dose adjustment is necessary for patients with mild, moderate, or severe renal impairment or end-stage renal disease. No dose adjustment is necessary for patients with hepatic impairment. ## Contraindications * Known hypersensitivity to linagliptin or any excipients in the formulation. ## Adverse Effects * **Common:** Nasopharyngitis, upper respiratory tract infection, cough. * **Serious:** Hypersensitivity reactions (including anaphylaxis, angioedema, rash, urticaria), severe and disabling arthralgia (joint pain), bullous pemphigoid. ## Key Drug Interactions * **CYP3A4 Inducers:** Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, phenobarbital) may decrease linagliptin exposure and efficacy. If used together, consider increased monitoring of glycemic control. * **Sulfonylureas:** Add-on therapy with linagliptin may increase the risk of hypoglycemia when used in combination with sulfonylureas. Consider a lower dose of the sulfonylurea. ## Monitoring * Monitor glycemic control (e.g., HbA1c) regularly. * Monitor for signs and symptoms of hypersensitivity reactions. * Monitor for symptoms of severe joint pain. * Monitor for bullous pemphigoid lesions. ## Clinical Pearls * Linagliptin is primarily eliminated unchanged by the liver and does not require dose adjustment in renal impairment, making it a useful option for patients with kidney disease. * While DPP-4 inhibitors are generally associated with a low risk of hypoglycemia, the risk increases when used in combination with other glucose-lowering agents known to cause hypoglycemia (e.g., insulin, sulfonylureas). * Rare cases of severe and disabling joint pain have been reported. Advise patients to seek medical attention if severe joint pain develops. *** *Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and local protocols before making any clinical decisions.*